Loading asset research
Aprea Therapeutics Inc. Common stock
APRENasdaq · USD · StocksQuote as of · Exchange session not verified$0.774
-1.90%
Today
APRE
Loading 1D prices…
Market cap
$9.7M
Volume
127.3K
52w high
$1.6952w low
$0.548Company profile
Aprea Therapeutics Inc. Common stock
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Doylestown, PA, United States
Employees
8
Fiscal year end
1231
CIK
1781983
Session & valuation
Open$0.796
Previous close$0.789
Day high$0.82
Day low$0.765
30-day avg. volume397.7K
Outstanding shares12.6M
Diluted EPS-$1.93
Latest annual period
P/E (trailing)-0.40
P/E (forward)-2.28
Price / book0.25
Beta1.63
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ENSCEnsysce Biosciences Inc. Common Stock | $9.5M | $5.1M | -200.84% | -$3.98 | -5.62% | Unrated |
| GDTCCytoMed Therapeutics Limited Ordinary Shares | $9.3M | — | — | -$0.39 | -1.84% | Unrated |
| MDCXMedicus Pharma Ltd. Common Stock | $10.3M | $0.00 | — | -$2.74 | +0.43% | Buy |
| XCURExicure Inc. Common Stock | $9.2M | $0.00 | — | -$0.79 | +2.19% | Unrated |
| XBIOXenetic Biosciences Inc. Common Stock | $9.1M | $3M | -90.07% | -$1.58 | -4.18% | Unrated |